未登录

W

Weihe Zhang

alabama 35244

H指数:21

被引数:1,962

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Activation of the bacterial defense-associated sirtuin system

细菌防御相关SirTuin系统的激活

COMMUNICATIONS BIOLOGY

IF5.1

2025-02-240

OA

Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

OA

Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2022-11-014

PRE

Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2022-11-013

PRE

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-08-2621

PRE

UNC5293, a potent, orally available and highly MERTK-selective inhibitor

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-08-017

PREAI

Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-04-0617

OAAI

Rohde, Jason M.; Karavadhi, Surendra; Pragani, Rajan; Liu, Li; Fang, Yuhong; Zhang, Weihe; McIver, Andrew; Zheng, Hongchao; Liu, Qingyang; Davis, Mindy, I; Urban, Daniel J.; Lee, Tobie D.; Cheff, Dorian M.; Hollingshead, Melinda; Henderson, Mark J.; Martinez, Natalia J.; Brimacombe, Kyle R.; Yasgar, Adam; Zhao, Wei; Klumpp-Thomas, Carleen; Michael, Sam; Covey, Joseph; Moore, William J.; Stott, Gordon M.; Li, Zhuyin; Simeonov, Anton; Jadhav, Ajit; Frye, Stephen; Hall, Matthew D.; Shen, Min; Wang, Xiaodong; Patnaik, Samarjit; Boxer, Matthew B.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2019-07-2516

OAAI

Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2018-10-2225

PREAI

The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

IF5

2018-02-0125

OAAI

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

CLINICAL CANCER RESEARCH

IF10.2

2017-03-1459

OAAI

Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors

大环嘧啶作为MerTK特异性抑制剂的发现

IF3.4

2017-01-0929

OAAI

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2016-09-2128

OAAI

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

IF6.1

2016-03-1765

OA

Recent Thymus Emigrant CD4+T Cells Predict HIV Disease Progression in Patients With Perinatally Acquired HIV

CLINICAL INFECTIOUS DISEASES

IF7.3

2016-02-2118

OAAI

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status

MOLECULAR CANCER THERAPEUTICS

IF5.5

2015-09-0259

OAAI

UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia

EUROPEAN JOURNAL OF CANCER

IF7.1

2014-11-010

PREAI

MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia

CANCER RESEARCH

IF16.6

2014-10-090

PRE

Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer

CANCER RESEARCH

IF16.6

2014-10-010

PRE

A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

CANCER RESEARCH

IF16.6

2014-10-011

PRE